Drug Profile
TD 3504
Alternative Names: TD-3504Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Theravance Biopharma
- Class
- Mechanism of Action Janus kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ulcerative colitis
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Ulcerative-colitis(In adults) in USA
- 08 Nov 2017 Theravance Biopharma completes a phase I trial in Ulcerative colitis (In adults) in USA (PO) (NCT03103412)
- 14 Nov 2016 Theravance Biopharma plans a phase I trial for Ulcerative colitis